HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

Abstract Background The treatment of hepatocellular carcinoma (HCC) patients exhibiting high-risk characteristics (Vp4, and/or bile duct invasion, and/or tumor occupancy ≥ 50%) lacks standardized approaches and yields unfavorable results. This study endeavors to evaluate the safety, efficacy, and pr...

Full description

Bibliographic Details
Main Authors: Xu Chang, Xinge Li, Peng Sun, Zhenfeng Li, Pengfei Sun, Shangkun Ning
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Cancer
Subjects:
HCC
HAIC
Lenvatinib
PD-1
High-risk
Online Access:https://doi.org/10.1186/s12885-024-12233-6

Internet

https://doi.org/10.1186/s12885-024-12233-6

Similar Items